| scholarly article | Q13442814 |
| P50 | author | George Simos | Q40007045 |
| Panagiotis Liakos | Q56515740 | ||
| P2093 | author name string | Christos N Papandreou | |
| Panagiotis J Vlachostergios | |||
| Anna Patrikidou | |||
| Christina D Befani | |||
| Eleana Hatzidaki | |||
| Sophia Bonanou | |||
| P2860 | cites work | Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment | Q24306129 |
| Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases | Q28139317 | ||
| PI3K/PTEN signaling in angiogenesis and tumorigenesis | Q28383083 | ||
| Transformation of mammalian cells by constitutively active MAP kinase kinase | Q29618686 | ||
| Bortezomib is an efficient agent in plasma cell leukemias | Q33364213 | ||
| MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300 | Q34177495 | ||
| Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression | Q34300719 | ||
| Development of the proteasome inhibitor Velcade (Bortezomib). | Q34327233 | ||
| Bortezomib as a potential treatment for prostate cancer | Q35853743 | ||
| Hypoxia-inducible factor-1 in human breast and prostate cancer | Q36586164 | ||
| The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics | Q36760971 | ||
| Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model | Q36841356 | ||
| Regulation of cancer cell metabolism by hypoxia-inducible factor 1. | Q37359659 | ||
| Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain | Q38407792 | ||
| The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions | Q39691467 | ||
| Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors | Q40169606 | ||
| Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells | Q40302603 | ||
| The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer | Q40353039 | ||
| Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib | Q40442471 | ||
| Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells | Q40579506 | ||
| Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells | Q42771053 | ||
| Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha | Q43578303 | ||
| Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells | Q44509691 | ||
| Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma | Q44662272 | ||
| Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA. | Q45027272 | ||
| Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells | Q46431072 | ||
| Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. | Q46805949 | ||
| Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. | Q46823917 | ||
| Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity | Q46864477 | ||
| Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells | Q46882677 | ||
| Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. | Q50716537 | ||
| Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. | Q50933268 | ||
| p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. | Q52173333 | ||
| Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib | Q60464840 | ||
| Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer | Q73144135 | ||
| P2507 | corrigendum / erratum | Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. | Q46487604 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 45-54 | |
| P577 | publication date | 2011-09-10 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells | |
| P478 | volume | 90 |
| Q41564669 | 22-S-Hydroxycholesterol protects against ethanol-induced liver injury by blocking the auto/paracrine activation of MCP-1 mediated by LXRα. |
| Q26849940 | Advances in the understanding of mechanisms and therapeutic use of bortezomib |
| Q90150620 | Anti-tumor Effect of Ginkgo biloba Exocarp Extracts on B16 Melanoma Bearing Mice Involving P I3K/Akt/HIF-1α/VEGF Signaling Pathways |
| Q33906104 | Antiangiogenic activity of phthalides-enriched Angelica Sinensis extract by suppressing WSB-1/pVHL/HIF-1α/VEGF signaling in bladder cancer |
| Q34171130 | Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells |
| Q92073938 | Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer |
| Q34662185 | Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. |
| Q36095138 | Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1α expression |
| Q39156092 | Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. |
| Q52874910 | Bortezomib sensitizes esophageal squamous cancer cells to radiotherapy by suppressing the expression of HIF-1α and apoptosis proteins. |
| Q37373595 | Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells |
| Q55417331 | Control of Hedgehog Signalling by the Cilia-Regulated Proteasome. |
| Q47605343 | Effect of low-frequency low-intensity ultrasound with microbubbles on prostate cancer hypoxia |
| Q35807838 | Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. |
| Q39145987 | Functional exploration of colorectal cancer genomes using Drosophila |
| Q34515298 | Genome Resequencing Identifies Unique Adaptations of Tibetan Chickens to Hypoxia and High-Dose Ultraviolet Radiation in High-Altitude Environments |
| Q38825960 | HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies |
| Q39324644 | HIF-1α induced by β-elemene protects human osteosarcoma cells from undergoing apoptosis |
| Q36238647 | HIF-1α pathway: role, regulation and intervention for cancer therapy |
| Q36304372 | High altitude hypoxia as a factor that promotes tibial growth plate development in broiler chickens |
| Q38097867 | Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. |
| Q41913079 | Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment |
| Q36220497 | Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy |
| Q28393898 | Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells |
| Q36413454 | IKK inhibition increases bortezomib effectiveness in ovarian cancer |
| Q39003629 | KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells |
| Q35890752 | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| Q27025007 | Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality |
| Q39084498 | MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma |
| Q39051696 | Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits hypoxia-induced neovasculogenesis through prolyl hydroxylase, von Hippel-Lindau-dependent pathway. |
| Q38081415 | Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? |
| Q36229899 | Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound |
| Q35038458 | Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options |
| Q37088364 | Quercetin alleviates pulmonary angiogenesis in a rat model of hepatopulmonary syndrome |
| Q36658324 | Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy |
| Q36781055 | Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway |
| Q35863135 | Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma |
| Q64244093 | Synergistic Effects of Bortezomib-OV Therapy and Anti-Invasive Strategies in Glioblastoma: A Mathematical Model |
| Q26746930 | The cilia-regulated proteasome and its role in the development of ciliopathies and cancer |
| Q38069898 | Therapeutic targeting of cancer cell cycle using proteasome inhibitors |
| Q50057427 | Tibial dyschondroplasia is closely related to suppression of expression of hypoxia-inducible factors 1α, 2α, and 3α in chickens |
| Q38828535 | VEGFR2 inhibition by RNA interference affects cell proliferation, migration, invasion, and response to radiation in Calu-1 cells |
| Q64274822 | Vanillic Acid Suppresses HIF-1α Expression via Inhibition of mTOR/p70S6K/4E-BP1 and Raf/MEK/ERK Pathways in Human Colon Cancer HCT116 Cells |
| Q35790990 | Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment |
| Q46487604 | Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. | main subject | P921 |
Search more.